Starling Oncology, Inc.: stockholders equity
Stockholders equity for Starling Oncology, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Starling Oncology, Inc. financial histories
What this measure means
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
Exact concept: us-gaap:StockholdersEquity. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2019-10-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | -15,720,000 | USD | 2026-03-12 | 10-K · 0001799191-26-000007 |
| At date | 2024-12-31 | 3,589,000 | USD | 2026-03-12 | 10-K · 0001799191-26-000007 |
| At date | 2023-12-31 | 57,025,000 | USD | 2026-03-12 | 10-K · 0001799191-26-000007 |
| At date | 2022-12-31 | 123,175,000 | USD | 2025-03-26 | 10-K · 0001799191-25-000014 |
| At date | 2021-12-31 | 104,159,000 | USD | 2024-03-28 | 10-K · 0001628280-24-013444 |
| At date | 2020-12-31 | 28,101,000 | USD | 2023-03-16 | 10-K · 0001628280-23-008315 |
| At date | 2020-09-30 | -21,507,440 | USD | 2021-12-14 | 10-K/A · 0001104659-21-149304 |
| At date | 2020-06-30 | -19,090,780 | USD | 2021-12-14 | 10-K/A · 0001104659-21-149304 |
| At date | 2020-03-31 | -16,472,045 | USD | 2021-12-14 | 10-K/A · 0001104659-21-149304 |
| At date | 2020-03-13 | -16,043,066 | USD | 2021-12-14 | 10-K/A · 0001104659-21-149304 |
| At date | 2019-12-31 | 42,222,000 | USD | 2022-03-11 | 10-K · 0001628280-22-005868 |
| At date | 2019-10-31 | 0 | USD | 2021-12-14 | 10-K/A · 0001104659-21-149304 |
Related financial histories
- Starling Oncology, Inc.: total assets
- Starling Oncology, Inc.: total liabilities
- Starling Oncology, Inc.: net income or loss
- Starling Oncology, Inc.: operating cash flow
- Starling Oncology, Inc.: capital expenditure payments
- Starling Oncology, Inc.: contract revenue excluding tax
- Starling Oncology, Inc.: financing cash flow
- Starling Oncology, Inc.: investing cash flow
- Starling Oncology, Inc.: retained earnings or deficit
- Starling Oncology, Inc.: basic weighted-average shares
- Starling Oncology, Inc.: diluted weighted-average shares
- Starling Oncology, Inc.: basic earnings per share
- Starling Oncology, Inc.: diluted earnings per share
- Starling Oncology, Inc.: income tax expense or benefit
- Starling Oncology, Inc.: net property, plant and equipment
- Starling Oncology, Inc.: share-based compensation expense
- Starling Oncology, Inc.: operating income or loss
- Starling Oncology, Inc.: current assets
- Starling Oncology, Inc.: current liabilities
- Starling Oncology, Inc.: current accounts payable
- Starling Oncology, Inc.: goodwill carrying amount
- Starling Oncology, Inc.: net finite-lived intangible assets
- Starling Oncology, Inc.: net current accounts receivable
- Starling Oncology, Inc.: common-stock repurchase payments
- Starling Oncology, Inc.: net inventory
- Starling Oncology, Inc.: selling, general and administrative expense
Inspect the source
- Entity
- Starling Oncology, Inc. / CIK 0001799191
- Captured
- 2026-09-21T17:32:27.176Z
- SEC response SHA-256
f73886b3a6ef18eabd171f881d98188fdae3395c8278a3e8cf17563c6ab57c88
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001799191.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))